Introduction
Throughout the history of the world, the ones who had confronted the bitterest face of poverty and war had always been the women. As known poverty and war affects human health either directly or indirectly, the effects of this condition on health and status of women in the society should not be ignored. This study intends to cast light on the effects of war and poverty on the reproductive health of women. For this purpose, the face of war affecting the women, the problem of immigration, inequalities in distribution of income based on gender and the effects of all these on the reproductive health of women will be addressed.
War and Women's Health
Famine, synonymous with war and poverty, is clearer for women; war means deep disadvantages such as full destruction, loss of future and uncertainty for women. Wars are conflicts that destroy families, societies and cultures that negatively affect the health of community and cause violation of human rights. According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1) . War has many negative effects on human health. One of these is its effect of shortening the average human life. According to the data of WHO, the average human life is 68.1 years for males and 72.7 years for females. It is being thought that severe military conflicts in Africa shorten the expected lifetime for more than 2 years. In general, WHO had calculated that 269 thousand people had died in 1999 due to the effect of wars and that loss of 8.44 million healthy years of life had occurred (2, 3) . Wars negatively affect the provision of health services. Health institutions such as hospitals, laboratories and health centers are direct targets of war. Moreover, the wars cause the migration of qualified health employees, and thus the health services hitches. Assessments made indicate that the effect of destruction in the infrastructure of health continues for 5-10 years even after the finalization of conflicts (3) . Due to resource requirements in the restructuring investments after war, the share allocated to health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and children. While deaths depending on direct violence affect the male population, the indirect deaths kill children, women and elders more. In Iraq between 1990-1994, infant deaths had shown this reality in its more bare form with an increase of 600% (4). The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5) . As the result of wars and armed conflicts, women are Abstract War and poverty are 'extraordinary conditions created by human intervention' and 'preventable public health problems. ' War and poverty have many negative effects on human health, especially women's health. Health problems arising due to war and poverty are being observed as sexual abuse and rape, all kinds of violence and subsequent gynecologic and obstetrics problems with physiological and psychological courses, and pregnancies as the result of undesired but forced or obliged marriages and even rapes. Certainly, unjust treatment such as being unable to gain footing on the land it is lived (asylum seeker, refugee, etc.) and being deprived of social security, citizenship rights and human rights brings about the deprivation of access to health services and of provision of service intended for gynecology and obstetrics. The purpose of this article is to address effects of war and poverty on the health of reproduction of women and to offer scientific contribution and solutions. Keywords: Poverty, Reproductive health, War study groups. Finally, the differentiations of ovarian masses from benign to malignant were based from the pathologist's report. Patients diagnosed with ovarian cancer were differentiated based on the Federation of Obstetrics and Gynecology Guidelines (FIGO) (6) then the type, stage and grade of tumor were determined. After explaining the aim of the study to the subjects and after obtaining their written consent and ensuring about the confidentiality of their personal information, 5 ml. of blood was collected from both groups a day before surgery. Blood samples were immediately centrifuged at around 3000 rpm for 10 minutes at 4°C; the supernatant serum was collected and kept at -70°C up to the time when the study population's HE4, CA125 and ROMA were tested. Sampling intervals and freezing were at a maximum of one hour. After determining the serum values of HE4 and CA125, the ROMA was calculated using the two tumor markers. Measurement of the series of CA125 and HE4 values were performed using chemiluminescent enzyme immunoassay and electro chemiluminescent enzyme immunoassay, respectively. ROMA was calculated based on the following formula: Pre-menopausal predictive index (PZ) = -12 + 2.38 LN (HE4) + 0.0626 × LN (CA125) and post-menopausal predictive index (PZ) = -8.09 + 1.04 × LN (HE4) + 0.732 × LN (CA125). The cut off value of 35 u/ml for CA125 and HE4 based on the study of Nolen et al (7) and a pM of 70 was considered. ROMA cuff off for patients with high risk of ovarian cancer in pre-menopausal women were considered as ≥13.1% and for menopausal women as ≥27.7%, respectively based on the study conducted by Moore et al (4) . Based on ROMA result subjects were differentiated into low risk and high risk groups. Data from this present study was gathered using the following methods; descriptive statistics (mean ± SD), Fisher exact test, chi-square test, ROC curve and calculation of sensitivity-specificity. Statistical analyses were performed using SPSS 19 with normal results. Distribution of data was evaluated with the use of Kolmogorov-Smirnov test. P value of less than 0.05 was considered statistically significant.
Results
From the 67 patients with benign ovarian tumors, the most common histological type was endometrioma (29.9%) ( Table 1 ). Serous adenocarcinoma is the most common malignant tumor of the ovary (48.5%), stage 3 (57.6%) and grade 3 (90.9%) were the most common stage and grade, respectively ( Table 2) . Average HE4 in patients with malignant ovarian tumors was 278.33 ± 86.52 and for benign tumors was 40.25 ± 2.39 and the mean HE4 between the benign group and malignant group was P = .001which was significant. Average CA125 in patients with malignant ovarian tumors was 324.98 ± 98 and for benign tumors was 10.22 ± 50.11%, respectively and the difference of the CA125 level between benign and malignant groups was statistically significant (P ≥ .001).
Average ROMA in patients with malignant ovarian tumors was 67.51 ± 2.5% and for patients with benign tumors was 7.6 ± 1.1% and the difference of the ROMA level between these 2 groups was statistically significant (P ≥ .001). Table 3 shows the values of ROMA, CA125 and HE4 in patients with malignant tumors based on their different stages and grades. The difference between the average CA125 in patients with stage I-II (early stage) ovarian cancer in comparison to the levels of CA125 in patients with stage III-IV (advanced stage) ovarian cancer were not statistically significant. The average HE4 in patients with stage I-II ovarian cancer was (P = .04). There was no significant difference found between the average ROMA in patients with stage I-II in comparison to patients with stage III-IV ovarian cancer (P = .25). The mean ROMA levels in patients with grades I-II ovarian cancer were not statistically significant in comparison to the ROMA levels in patients with grades III-IV ovarian cancer (P = .59). In patients with benign ovarian mass the mean CA125 in menopausal women was 23.9 ± 14.8 and in non-menopausal women was 55.2 ± 12.1. Considering P=0.058 there were no meaningful statistical differences between 2 groups namely menopausal and non-menopausal. The mean HE4 in menopausal women was 45.3 ± 9.7 and in non-menopausal women 39.2 ± 20.9. Considering P = .04 there was a meaningful statistical difference between 2 menopausal and non-menopausal groups. The mean ROMA in menopausal women was 10.8 ± 5.6 and in non-menopausal women was 6.97 ± 1.38. Considering P = .94 there were no meaningful statistical differences between 2 groups. In patients with malignant ovarian mass the mean CA125 in menopausal women was 437.5 ± 193.2 and in non-menopausal women was 219.06 ± 59.9. Considering P = .17 the statistical difference between two groups was not meaningful. The mean HE4 in menopausal women was 357.1 ± 154.8 and in non-menopausal women 204.1 ± 84.9. Considering P = .2 there was no meaningful statistical difference between two menopausal and non-menopausal groups. The mean ROMA in menopausal women was 47.8 ± 36 and in non menopausal women was 86.01 ± 48.9. Considering P = .16 there were no meaningful statistical differences between two groups. Finally, based on the ROC curve, ROMA, HE4, and CA125 values for the diagnosis of malignant ovarian tumors were compared and it was observed that they have high diagnostic value in ovarian cancer. The AUC of these 3 methods were calculated and no significant differences were observed (AUC of CA125, HE4 and ROMA were 82.4%, 84.1%, 82.4% respectively) (Figure1).
In the assessment of the curves obtained, if 45.5 is considered to be the cut off value for CA125, the sensitivity would be considered as 84.8% and the specificity 74.1%, respectively. With regards to HE4, if 50.9 is considered to be the cut off value, this test would have a sensitivity of 75.8% and specificity of 74.6%. Regarding ROMA, if 9.4 is considered to be the cut off value, the sensitivity would be 75.8% and specificity would be 74.6%.
In considering that several studies regarding the etiology and risk factors of non-mucinous ovarian tumors and mucinous ovarian tumors yield different results, therefore, the mean of the three tumor markers among patients with mucinous ovarian tumors were compared with non-mucinous ovarian tumors with the following result: mean CA125 in patients with non-mucinous malignant patho-logic ovarian malignancy was 290.5 ± 51 and for patients with mucinous ovarian tumor was 432.4 ± 392, respectively (P = .009). Mean HE4 in patients with mucinous ovarian carcinoma was 129 ± 59 and the mean for non-mucinous carcinoma was 111 ± 326 with P = .16 and finally the mean ROMA of mucinous ovarian carcinoma was 31.45 ± 12 and the mean for non-mucinous malignancies was 79 ± 33 (P = .4). Discussion HE4, as a single tumor marker, has the most sensitivity in differentiating ovarian tumors from benign masses and using both HE4 and CA125 has more exact predicting power than each of them alone (8) (9) (10) (11) . Our findings disagree with above result, while it is in accordance with findings of Van Gorp et al (10) . In Van Gorp et al study ROMA, HE4 in comparison with CA125 alone, did not have much more power in diagnosing ovarian cancer.
In the present study, the mean studied three tumor markers in patients with grade 1,2 ovarian cancer did not have difference with grade 3 patients. Also the mean CA125, ROMA between the 2 early stages (I,II) and advanced stage (III,IV) groups were not different but the mean HE4 marker in advanced stage was meaningfully more than early stage (I,II). Findings of the present study on grade of malignant tumors showed that despite the small number of the sample size, it did not match the findings of Van Gorp et al study (10) ; however in their study the level of the 3 tumor markers were significantly higher with increasing stage of the disease process.
In this present study, the 3 tumor markers ROMA, HE4 and CA125 in patients with ovarian cancer were highly significant however ROMA and HE4 are not more sensitive in differentiating malignancy before surgery in comparison to CA125. In considering the cost of these tests, it seems that it is more cost effective for patients to undergo a combined CA125 and HF4 test rather than the single CA125 test. Also, in the present study, the mean of the three tumor markers under study in patients having grade I and II ovarian cancer did not show any significant difference in comparison to patients having grade III ovarian carcinoma and also, no significant difference has been observed on the mean of the ROMA and CA125 between the 2 groups of patients having stage I-II ovarian cancer and patients with stage III-IV, respectively. But the mean of the tumor marker HE4 in the advanced stage of ovarian cancer was significantly higher in comparison to the early stage (I-II) of cancer. With regards to tumor grade, results of this present study showed that the mean of these three tumor markers in patients with grade (I-II) malignant tumors, despite the small number of the sample size, yield similar results to the study conducted by Van Gorp et al (10) . However, in their study the level of the 3 tumor markers mentioned above were significantly higher with increasing stage of the disease process.
Conclusion
In this study, all three tumor marker HE4, CA125 and ROMA were able to distinguish malignant from benign tumors, but the value of ROMA and HE4 in diagnosing ovarian cancer was not higher in comparison to CA125 alone. Despite the promising results in preliminary studies, in the present study, HE4 and ROMA measurements in comparison to CA125 alone was not of much help in diagnosing cancer.
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